statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akari Therapeutics Non-GAAP EPS of $0.00...

Akari Therapeutics Non-GAAP EPS of $0.00

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX PR Newswire NEW YORK, March 18, 2024 NEW YORK, March...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of Monteverde & Associates PC (the M&A Class Action Firm ), has recovered money for shareholders and is...

SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger   SDPI, MINM, SCX, AKTX

Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX  Get Free Report) in a research report issued to clients and investors on Friday. The...

Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm PR Newswire NEW YORK, March 15, 2024 NEW...

Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm

Equities researchers at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX  Get Free Report) in a research note issued to investors on Thursday. The brokerage set a...

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

NEW YORK, March 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek...

Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

Volume	22,039.00
52-Wk High	$5.50
52-Wk Low	$1.08

AKTX Akari Therapeutics

About

Feed

News

Fundamentals